Date: 2016-01-07
Type of information: Collaboration agreement
Compound:
Company: Ipsen (France) Aepodia (Belgium)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 7, 2016, Ipsen announced a partnership in the field of early stage clinical development. Its objective is to maximize Ipsen capacity to develop early clinical phase programs and Proof-of-Concept (POC) studies while expanding its R&D portfolio. Aepodia will provide its expertise and agility in early clinical development and in the implementation of Phase I studies up to Proof-of-Concept (POC), and will work with Ipsen teams to optimize the design of clinical studies and their operational implementation. Aepodia is the first company that will integrate into Ipsen’s existing R&D facilities in a new Open Innovation Campus in Les Ulis where Aepodia France staff will be located (affiliate of Aepodia Belgium).
Financial terms:
Latest news:
